Other Events ·
Satellos Granted Composition of Matter Patent for Forazapadin Through Sept. 6, 2044
MSLESatellos Bioscience Inc.
The United States Patent and Trademark Office issued U.S. Patent No. 12,747,245 covering composition of matter claims for forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors. The patent provides intellectual property protection through September 6, 2044, with potential eligibility for Patent Term Extension following future U.S. marketing approval. Forazapadin is currently advancing in Phase 2 development for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy. Satellos Bioscience Inc. operates as a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.